Systems and integrative biology as alternative guises for pharmacology: Prime time for an iPharm concept?

Biochemical Pharmacology

Volumn 70, Issue 12, 2005, Pages 1707-1716

  Williams, Michael ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Drug discovery; Integrative biology; iPharm; Null hypothesis; Pharmacology

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; IMATINIB; PROTEIN KINASE INHIBITOR; TIFLUADOM;

BINDING AFFINITY; BIOTECHNOLOGY; CANCER THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TRANSPORT; GENETIC TOXICOLOGY; LIVER MICROSOME METABOLISM; MEDICAL RESEARCH; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

EID: 27744572131     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.08.019     Document Type: Note

References (86)

1. B.S. Beckman Explore pharmacology: graduate studies in pharmacology 2003 American Society for Pharmacology and Experimental Therapeutics Bethesda, MD, September
2. In Vivo Pharmacology Training Group. The fall and rise of in vivo pharmacology. Trends Pharmacol Sci 2002;23:13-18.
3. B.B. Fredholm, W.W. Fleming, P.M. Vanhoutte, and T. Godfraind The role of pharmacology in drug discovery Nat Rev Drug Discov 1 2002 237 238
4. E. Zerhouni The NIH Roadmap Science 302 2003 63 72
5. Anon. Key facts: drugs, healthcare, economy. Les Enterprises du Medicament, Paris, France; 2003.
6. W. Sneader Drug discovery: the evolution of modern medicines 1985 Wiley Chichester, UK
7. J. Drews Drug discovery: a historical perspective Science 287 2000 1960 1964
8. J.P. Swann Academic scientists and the pharmaceutical industry 1988 Johns Hopkins Baltimore, MD
9. A.A. Daemmrich, and M.E. Bowden A rising drug industry Chem Eng News 83 25 2005 28 42
10. T. Kenakin A pharmacology primer. Theory application and methods 2004 Elsevier Academic Press San Diego, CA
11. Limbird LE The receptor concept: a continuing evolution Mol Interven 4 2004 326 336
12. T. Kenakin Pharmacologic analysis of drug-receptor interaction 2nd ed. 1997 Lippincott-Raven Philadelphia, PA pp. 344-346
13. M. Williams, C. Mehlin, and D.J. Triggle Receptor targets in drug discovery and development 6th ed. D. Abraham Burger's medicinal chemistry and drug discovery. Drug discovery and development vol. 2 2003 Wiley-Interscience Hoboken, NJ 319 355
14. J.G. Lombardino, and J.A. Lowe A guide to drug discovery: the role of the medicinal chemist in drug discovery - then and now Nature Rev Drug Discov 3 2004 853 862
15. M. MacCoss, and T.A. Baillie Organic chemistry in drug discovery Science 303 2004 1810 1813
16. J. Drews Genomic sciences and the medicine of tomorrow Nat Biotech 14 1996 1516 1518
17. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase component of the human genome Science 298 2002 1912 1934
18. M. Goozner The $800 million pill: the truth behind the cost of new drugs 2004 University of California Press Berkeley, CA
19. El Feki S. Prescription for change. Economist, 18 June; 2005.
20. Black J. A personal perspective on Dr. Paul Janssen. J Med Chem 2005;48:1687-1688.
21. S.W. Edwards, C.M. Tan, and L.L. Limbird Localization of G-protein-coupled receptors in health and disease Trends Pharmacol Sci 21 2000 304 308
22. M. Lutz, and P. Kenakin Quantitative molecular pharmacology and informatics in drug discovery 1999 Wiley Chichester, UK
23. Teitelman R. Gene dreams: wall street, academia, and the rise of biotechnology. Basic Books, New York; 1989.
24. A.S. Kesselheim, and J. Avorn University-based science and biotechnology products. Defining the boundaries of intellectual property J Am Med Assoc 293 2005 850 854
25. J. Paradise, L. Andrews, and T. Holbrook Patents on human genes: an analysis of scope and claims Science 307 2005 1566 1567
26. Pollack A. Court rules drug patents don't bar research by rivals. New York Times, 13 June; 2005.
27. J. Drews Strategic trends in the drug industry Drug Discov Today 8 2003 411 420
28. J. Avorn Powerful medicines: the benefits risk and costs of prescription drugs 2004 Knopf New York
29. R.H. Glassman, and A.Y. Sun Biotechnology: identifying advances from the hype Nat Rev Drug Discov 3 2004 177 183
30. M. Williams A return to the fundamentals of drug discovery Curr Opin Invest Drugs 5 2004 29 33
31. A. Prud'homme The cell game 2004 HarperCollins New York
32. M. Zuckoff Ponzi's scheme 2005 Random House New York
33. H. Kubinyi Drug research: myths, hype and reality Nat Rev Drug Discov 2 2003 665 668
34. E.C. Gunther, D.J. Stone, R.W. Gerwein, P. Bento, and M.P. Hayes Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro Proc Natl Acad Sci USA 100 2003 9608 9613
35. L.J. Gershell, and J.H. Atkins A brief history of novel drug discovery technologies Nat Rev Drug Discov 2 2003 321 327
36. J.S. Handen Drug discovery in the modern age; how we got here and what does it mean? J.S. Handen Industrialization of drug discovery: from target selection through lead optimization 2005 CRC Press/Taylor and Francis Boca Raton, FL 1 12
37. G.S. Firestein, and D.S. Pisetsky DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology Arthritis Rheum 46 2002 859 861
38. G. Duyk Attrition and translation Science 302 2003 603 605
39. G.M. Milne Jr. Pharmaceutical productivity - the imperative for new paradigms Ann Rep Med Chem 38 2003 383 396
40. J. Settleman Mutated kinases as targets for cancer drugs Drug Discov Today Dis Mechanisms 2 2005 139 144
41. J.M. Goldman A unifying mutation in chronic myleoproliferative disorders N Engl J Med 352 2005 1744 1746
42. T. Kenakin The classification of seven transmembrane receptors in recombinant expression systems Pharmacol Rev 48 1996 413 463
43. S. Maudsley, B. Martin, and L.M. Luttrell The origins of diversity and specificity in G protein-coupled receptor signalling J Pharmacol Exp Ther 314 2005 485 494
44. M.K. Dean, C. Higgs, R.E. Smith, R.P. Bywater, C.R. Snell, and P.D. Scott Dimerization of G-protein-coupled receptors J Med Chem 44 2001 4595 4614
45. S. Angers, A. Salahpour, and M. Bouvier Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function Ann Rev Pharamcol Toxicol 42 2002 409 435
46. M. Vieth, J.J. Sutherland, D.H. Robertson, and R.M. Campbell Kinomics: characterizing the therapeutically validated kinase space Drug Disc Today 10 2005 839 846
47. T. Kenakin Efficacy at G-protein-coupled receptors Nat Rev Drug Discov 1 2002 103 110
48. D.T. Chalmers, and D.P. Behan The use of constitutively active GPCRs in drug discovery and functional genomics Nat Rev Drug Discov 1 2002 599 608
49. D.F. Horrobin Realism in drug discovery - could Cassandra be right? Nat Biotech 19 2001 1099 1100
50. J.F. Pritchard, M. Jurima-Romet, M.L.J. Reimer, E. Mortimer, B. Rolfe, and N.M. Cayen A guide to drug discovery: making better drugs: decision gates in non-clinical drug development Nat Rev Drug Discov 2 2003 542 553
51. J. Hodgson ADMET? Turning chemicals into drugs Nat Biotech 19 2001 722 726
52. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26
53. D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates J Med Chem 45 2002 2615 2623
54. Ator MA, Williams M. Safety pharmacology III - target binding profile. xPharm, in press.
55. D.C. Swinney Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3 2004 801 808
56. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359
57. C.T. Keith, A.A. Borisy, and B.R. Stockwell Multicomponent therapeutic for networked systems Nat Rev Drug Discov 4 2005 71 78
58. M. Spedding, T. Jay, J. Costa e Silva, and L. Perret A pathophysiological paradigm for the therapy of psychiatric disease Nat Rev Drug Discov 4 2005 467 478
59. M.A. Fabian, W.H. Biggs III, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, and M.G. Benedetti A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 23 2005 329 336
60. T.A. Carter, L.M. Wodicka, N.P. Shah, A.M. Velasco, M.A. Fabian, and D.K. Treiber Inhibition of drug-resistant mutants of ABL, KIT and EGF receptor kinases Proc Natl Acad Sci USA 102 2005 11011 11016
61. S.M. Abdel-Rahman, and R.E. Kauffman The Integration of pharmacokinetics and pharmacodynamics: understanding dose-response Ann Rev Pharmacol Toxicol 44 2004 111 136
62. R.R. Neubig, M. Spedding, T. Kenakin, and A. Christopoulos International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology Pharmacol Rev 55 2003 597 605
63. J. Black Drugs from emasculated hormones: the principle of syntopic antagonism Science 245 1989 486 493
64. B.P. Zambrowicz, and A.T. Sands Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2 2003 38 51
65. P.C. Jobe, L.E. Adams-Curtis, T.F. Burks, R.W. Fuller, C.C. Peck, and R.R. Ruffolo The essential role of integrative biomedical sciences in protecting and contributing to the health and well being of our nation Physiologist 37 1994 79 84
66. J. Maddox Is molecular biology yet a science? Nature 335 1992 201
67. K. Godl, J. Wissing, A. Kurtenbach, P. Habenberger, and S. Blencke An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc Natl Acad Sci 100 2003 15434 15439
68. S. Frantz In vivo we trust Nat Rev Drug Discov 2 2003 501
69. P.C. Preusch Integrative and organ systems pharmacology: a new initiative from the National Institute of General Medical Sciences Mol Interv 4 2004 72 73
70. 4 that mediates chemotaxis Nature 387 1997 620 624
71. G.K.M. Akbar, V.R. Dasari, T.E. Webb, K. Ayyanathan, K. Pillarisetti, and A.K. Sandhu Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells J Biol Chem 271 1996 18363 18367
72. D.F. Horrabin Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2 2003 151 154
73. S.B. Powell, V.B. Risbrough, and M.A. Geyer Potential use of animal models to examine antipsychotic prophylaxis for schizophrenia Clin Neurosci Res 3 2003 289 296
74. R.D. Porsolt, G. Anion, N. Blavet, and M. Jalfre Behavioral despair in rats: a new model sensitive to antidepressant treatments Eur J Pharmacol 47 1977 379 391
75. J.F. Cryan, and A. Holmes The ascent of mouse: advances in modelling human depression and anxiety Nat Rev Drug Discov 4 2005 775 790
76. B.S. McEwen Allostatis and allostatic load-implications for neuropsychopharmacology Neuropsychopharmacology 22 2001 108 124
77. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, and S. Dulawa Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805 809
78. Porsolt R, Williams M. Safety pharmacology. xPharm, in press.
79. T.O. Joos, and J. Bachmann The promise of biomarkers: research and applications Drug Discov Today 10 2005 615 616
80. FDA. Innovation/stagnation. Challenge and opportunity on the critical path to new medical products. Bethesda, MD: FDA, April; 2004 [www.fda.gov/oc/initiatives/criticalpath/whitepaper.html].
81. E. Grazzini, C. Puma, M.-O. Roy, X.H. Yu, D. O'Donnell, and R. Schmidt Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats Proc Natl Acad Sci 101 2004 7175 7180
82. J. Couzin NIH dives into drug discovery Science 302 2003 218 221
83. L. Hood, J.R. Heather, M.E. Phelps, and B. Lin Systems biology and new technologies enable predictive and preventative medicine Science 306 2004 640 643
84. E.C. Butcher Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 4 2005 461 467
85. R.B. Stoughton, and S.H. Friend How molecular profiling could revolutionize drug discovery Nat Rev Drug Discov 4 2005 345 350
86. S. Schrieber Target-oriented and diversity-oriented organic synthesis in drug discovery Science 287 2000 1964 1969